HA
Highly rated in
30
conditions
Highly rated in
30
conditions

About Dr. Hassan Abolhassani

Hassan Abolhassani is in Huddinge, Sweden. Dr. Abolhassani is highly rated in 30 conditions, according to our data. His top areas of expertise are Common Variable Immune Deficiency, Immunodeficiency with Hyper IGM Type 1, X-Linked Agammaglobulinemia, and Selective Deficiency of IgA.

His clinical research consists of co-authoring 219 peer reviewed articles in the past 15 years.

Locations
  Huddinge, AB, SE
Background & Education
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


219 Total Publications

Journal: Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology
Published —June 28, 2021
Known and Potential Molecules Associated with Altered B cell Development Leading to Predominantly Antibody Deficiencies.


Save this doctor for later
Sign Up
Is this your doctor?
Find a second opinion
Find Now
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
Highly rated in
0
conditions
Karolinska University Hospital
 
Stockholm, AB, SE 
 11.6 km
Ingrid Lundberg is in Stockholm, Sweden. They have been an author on 228 peer reviewed articles and participated in 44 clinical trials in the past 15 years.
Highly rated in
0
conditions
Karolinska University Hospital
 
Stockholm, AB, SE 
 11.6 km
Henrik Falhammar is in Stockholm, Sweden. They have been an author on 185 peer reviewed articles in the past 15 years.
Highly rated in
0
conditions
Karolinska University Hospital
 
Stockholm, AB, SE 
 11.6 km
Helene Alexanderson is in Stockholm, Sweden. They have been an author on 69 peer reviewed articles and participated in 3 clinical trials in the past 15 years.